ADHD medication crash and rebound: what the terms mean and what evidence shows

Adults often describe a "crash" or "mood crash" when ADHD medication fades: sudden tiredness, a short temper, tears, or a feeling that focus has fallen off a cliff. The experience can be real and disruptive. The word itself is less precise than it sounds, and the research behind it is thinner than online discussion suggests. This page separates what FDA labels (checked on DailyMed on November 4, 2026) and studies actually say from common usage. It gives no dosing information and is not advice to change how you take your medication.

What the labels say, and what they do not

This page searched the current labels for Adderall XR, Vyvanse, Concerta, Strattera and Qelbree for these two words.

• "Crash." It does not appear in any of them. A label's silence does not mean nobody feels this way. It means the term has no labeled definition.
• "Rebound" for stimulants. In the Concerta and Vyvanse labels the word appears only in a passage about growth in children, not about mood or symptoms in the evening.
• "Rebound" for atomoxetine. The Strattera label says there was no evidence of symptom rebound or a withdrawal syndrome after discontinuation.
• "Rebound" for guanfacine. The Intuniv label uses it for something else: rebound high blood pressure after abrupt stopping. That is a physical safety issue, and it is one reason not to stop that medication suddenly.

Labels do list nearby effects. In the adult Concerta trials, irritability was reported by 6% against 1% on placebo, and depressed mood by 4% against 1%. Among reactions reported after approval, the Adderall XR label lists irritability, dysphoria (an uneasy, unhappy mood) and depression. These figures do not say when in the day the effects occurred, so they cannot confirm or rule out a late-day pattern.

What research shows about rebound

Researchers define rebound as a deterioration in behavior or symptoms as medication wears off. Definitions and measures vary, and nearly all the direct evidence comes from children.

• Carlson and Kelly, 2003. Nurses compared evening and day behavior in 149 psychiatrically hospitalized children on short-acting stimulants. Rebound was seen in 30% on at least one dose, and it was serious enough to stop treatment in 8.7%. Hospitalized children on short-acting drugs differ from adults at work on modern extended-release products.
• Lopez and colleagues, 2017. In a post hoc analysis of a trial in children aged 6 to 12, parent ratings showed rebound in 3.4% on lisdexamfetamine and 9.7% on placebo. That placebo rate is a useful caution: symptoms can look worse late in the day without any stimulant wearing off. Children who did rebound on lisdexamfetamine had higher emotional lability scores.
• Adler and colleagues, 2017. Forty adults took open-label lisdexamfetamine for up to 12 weeks, and the authors reported limited symptom rebound. The study also tested a new adult rebound rating scale. With no placebo group and a small sample, it cannot tell you how common rebound is in adults.
• Buitelaar and colleagues, 2012. After long-term open-label OROS methylphenidate in adults, a small double-blind phase (23 continued, 22 switched to placebo) found no evidence of withdrawal or rebound after discontinuation. This looked at stopping, not the daily fade.

The honest summary: rebound has been observed, and it seems to affect a minority of children in the studies above. As of November 2026, a PubMed search for rebound studies in adults, run for this page, found no good estimate of how often adults get a daily rebound or "crash" on prescribed medication, and no controlled trial of what relieves it.

Where the word "crash" comes from

In addiction medicine, the term has a specific meaning. SAMHSA's treatment protocol on stimulant use disorders says a binge ends with acute withdrawal, "often called a 'crash'", marked by dysphoria, anxiety and agitation, along with fatigue, increasing depression and low energy. That describes heavy, repeated stimulant use in people with stimulant use disorders. A tired, irritable hour at 5 p.m. on a prescribed dose may share the name, but this research does not show it is the same thing. Using the same word for both can scare people, and it can hide a real problem if someone is taking more than prescribed.

How it differs from look-alikes

The clues in this table are practical sorting aids, not diagnostic rules, and these can overlap. See tolerance and wearing off, stopping ADHD medication and ADHD medication and mood changes. ADHD itself can also involve emotional swings, as covered in emotional dysregulation in adult ADHD, and depression can coexist with it, as explained in ADHD and depression in adults.

Things worth logging

The same search found no study testing whether skipped meals, short sleep or caffeine cause a late-day crash. They are still worth logging, because labels list appetite loss and insomnia as common effects of these medications, and because they are easy to confuse with a medication effect. NICE's strategies for weight loss on medication include adding meals or snacks when stimulant effects have worn off, which is a reminder that many people eat little until then.

For one or two weeks, write down:

• When you took the medication, and when the dip started and ended.
• What it felt like, in your own words, and how strong it was from 0 to 10.
• Whether you ate lunch, how you slept, and any caffeine or alcohol. See caffeine.
• Whether it happens on days you do not take medication, if your prescriber has told you to skip any days.
• Whether the same dip came before you started treatment.
• Whether anyone at home has noticed a pattern.

Raising it with your prescriber

NICE says a medication review should cover how well current treatment is working throughout the day, so this is an expected topic. Try saying: "Around 4 p.m. most days I get tearful and exhausted for about an hour. Here is my log." Then ask whether this looks like wearing off, rebound, a side effect or something separate, and whether timing, formulation or a different medication is worth considering. There is little direct evidence comparing those options for rebound in adults, so a change is often a monitored trial for you and your prescriber to judge together. Do not add a dose, skip a dose or stop on your own. Labels describe taking medication other than as prescribed as misuse, and they describe withdrawal after abrupt stopping or dose reduction following prolonged use.

When to call, and when it is urgent

• Call your prescriber soon if the dips interfere with work, driving or relationships, if low mood lasts beyond the dip, if you feel an urge to take more to avoid it, or if you are thinking of stopping.
• Call your prescriber right away for new or worsening mental symptoms, especially hearing voices, seeing or believing things that are not real, or new manic symptoms, as Medication Guides advise. The Qelbree label also reports higher rates of suicidal thoughts and behaviors than placebo and asks patients to report unusual changes in mood.
• Call or text 988 for thoughts of suicide or self-harm, at any hour. Call 911 if someone is in immediate danger. Do not wait to see whether the feeling passes when the next dose starts.
• Call 911 or go to the emergency room for chest pain, shortness of breath or fainting, which Medication Guides list as signs of heart problems.

Dr. Shershow evaluates and treats adults with ADHD located in New York or New Jersey, including medication management when medication is appropriate. See adult ADHD treatment.